Gene- and Cell-Based Therapies: CRISPR, Stem Cells, and Beyond
FluidFM BOT BIO Series – Boost CRISPR efficiency by direct delivery into the nucleus.
At the congress, we will present our unique FluidFM BOT BIO Series, a highly automated solution coupled to a fully automated Olympus IX83 inverted microscope with fluorescence. With it, deliver your CRISPR-Cas complexes directly where they are required: the nucleus. This avoids the risk of degradation of the repair template in the cytoplasm, therefore increasing the chance of HDR. Whether you are working with hard-to-transfect cells like iPSCs or a standard cell line such as CHO cells, you can selectively choose the cells you want to inject within a cell culture without affecting the neighboring cells. In contrast to many conventional transfection methods, no toxic compounds are necessary to allow the complexes to enter the cell. The gentle injection process preserves cell viability over 95%.
FluidFM – GO BEYOND.
About the meeting
Over the past several years, gene therapies and cell-based immunotherapies for cancer have become a reality, with several products approved by US and EU regulatory agencies and numerous clinical trials ongoing. Gene-editing approaches leveraging programmable nucleases, such as CRISPR-Cas9, have invigorated work in this area, as evidenced by a bolus of high-impact papers and a flood of biotechnology companies seeking to bring edited therapeutics to the market. The potential of targeted gene editing to personalize stem-cell-based therapies for degenerative disease and regenerative medicine is likewise the subject of intense preclinical interest. This meeting will bring together academic and industry scientists and clinicians working on developing and implementing gene therapy and cell-based therapy for a wide variety of conditions.
Meet us there at the booth with Olympus
For more information on the event, please go to the website of the Cell Symposia: Gene- and Cell-Based Therapies: CRISPR, Stem Cells, and Beyond.